X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (72) 72
female (64) 64
index medicus (59) 59
male (58) 58
middle aged (54) 54
oncology (54) 54
aged (53) 53
adult (45) 45
cancer (31) 31
chemotherapy (27) 27
lung neoplasms - drug therapy (27) 27
care and treatment (21) 21
lung cancer (21) 21
treatment outcome (21) 21
carcinoma, non-small-cell lung - drug therapy (20) 20
medicine & public health (19) 19
pharmacology & pharmacy (18) 18
analysis (17) 17
lung cancer, non-small cell (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
dose-response relationship, drug (15) 15
pharmacology/toxicology (15) 15
research (14) 14
tumors (14) 14
lung neoplasms - pathology (13) 13
antineoplastic agents - adverse effects (12) 12
medical research (12) 12
neoplasm staging (12) 12
neoplasms - drug therapy (12) 12
toxicity (12) 12
antineoplastic agents - therapeutic use (11) 11
cisplatin (11) 11
non-small cell lung cancer (11) 11
trial (11) 11
aged, 80 and over (10) 10
cancer research (10) 10
lung neoplasms - mortality (10) 10
medicine, experimental (10) 10
patients (10) 10
pharmacokinetics (10) 10
animals (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
drug administration schedule (9) 9
expression (9) 9
japan (9) 9
maximum tolerated dose (9) 9
original (9) 9
respiratory system (9) 9
retrospective studies (9) 9
safety (9) 9
angiogenesis (8) 8
asian continental ancestry group (8) 8
carboplatin (8) 8
cisplatin - administration & dosage (8) 8
disease-free survival (8) 8
dosage and administration (8) 8
hematology, oncology and palliative medicine (8) 8
metastasis (8) 8
oncology, experimental (8) 8
pharmacology (8) 8
survival (8) 8
antineoplastic agents - pharmacokinetics (7) 7
carcinoma, non-small-cell lung - mortality (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
cell line, tumor (7) 7
genetic aspects (7) 7
lung neoplasms - metabolism (7) 7
medical colleges (7) 7
mice (7) 7
solid tumors (7) 7
studies (7) 7
antineoplastic agents - administration & dosage (6) 6
carcinoma, squamous cell - drug therapy (6) 6
complications and side effects (6) 6
docetaxel (6) 6
gastroenterology & hepatology (6) 6
genotype (6) 6
hepatitis c (6) 6
hepatitis c virus (6) 6
interferon (6) 6
lung cancer, small cell (6) 6
mutation (6) 6
original article (6) 6
paclitaxel - administration & dosage (6) 6
phase-iii trial (6) 6
prognosis (6) 6
recombinant proteins - therapeutic use (6) 6
antimitotic agents (5) 5
antineoplastic agents (5) 5
antiviral agents - therapeutic use (5) 5
biological response modifiers (5) 5
carboplatin - administration & dosage (5) 5
carcinoma (5) 5
carcinoma, non-small-cell lung - metabolism (5) 5
cisplatin - adverse effects (5) 5
clinical trials (5) 5
drug therapy (5) 5
drug therapy, combination (5) 5
etoposide (5) 5
follow-up studies (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2007, Volume 13, Issue 10, pp. 2970 - 2976
PURPOSE: The anticancer agent indisulam is metabolized by the cytochrome P450 of enzymes CYP2C9 and CYP2C19. Polymorphisms of these enzymes may affect the... 
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2017, Volume 35, Issue 2, pp. 217 - 226
Objectives To determine the recommended dose and efficacy/safety of docetaxel combined with resminostat (DR) in non-small cell lung cancer (NSCLC) patients... 
Histone deacetylase inhibitor | Medicine & Public Health | Randomized phase II | Non-small cell lung cancer | Docetaxel | Oncology | Pharmacology/Toxicology | Resminostat | MULTICENTER | PLACEBO | ROMIDEPSIN | TRIAL | ONCOLOGY | DOUBLE-BLIND | LYMPHOMA | PHARMACOLOGY & PHARMACY | JAPANESE PATIENTS | NIVOLUMAB | EXPRESSION | ERLOTINIB | Lung Neoplasms - drug therapy | Humans | Hydroxamic Acids - adverse effects | Lung Neoplasms - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Platinum Compounds - therapeutic use | Histone Deacetylase Inhibitors - pharmacokinetics | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - metabolism | Treatment Outcome | Sulfonamides - pharmacokinetics | Hydroxamic Acids - pharmacokinetics | Taxoids - pharmacokinetics | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Hydroxamic Acids - therapeutic use | Aged | Histone Deacetylase Inhibitors - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Histone Deacetylase Inhibitors - adverse effects | Chemotherapy | Usage | Care and treatment | Safety and security measures | Dosage and administration | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
Cancer Science, ISSN 1347-9032, 11/2016, Volume 107, Issue 11, pp. 1642 - 1646
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2017, Volume 35, Issue 2, pp. 207 - 216
Journal Article
Journal Article
BMJ Case Reports, ISSN 1757-790X, 03/2019, Volume 12, Issue 3, p. e228420
A 26-year-old healthy patient had a fever and chest pain three days after nasal carbon dioxide (CO2) laser surgery for chronic and allergic rhinitis. In the... 
Medical personnel | Pathogens | Pneumonia | Substance abuse treatment | Medical imaging | Embolisms | Carbon dioxide | Staphylococcus infections | Patients | Blood | Case studies | Pain | Antibiotics | Laser surgery | Surgery | Nose | Endocarditis
Journal Article
Cancer Science, ISSN 1347-9032, 03/2012, Volume 103, Issue 3, pp. 504 - 509
Olaparib (AZD2281) is an orally active Poly(ADP‐ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers... 
Piperazines - administration & dosage | Phthalazines - administration & dosage | Phthalazines - pharmacokinetics | Humans | Middle Aged | Male | Antineoplastic Agents - administration &